MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.
In the company’s news,
Seeking Alpha yesterday published the following article featuring CytRx: http://seekingalpha.com/article/1700372-cytrx-corporation-remains-an-undiscovered-opportunity-inthe-cancer-space?source=yahoo#comments_header
Released On: 4/8/2016
Views: 3858
Released On: 4/7/2016
Views: 4599
Released On: 3/31/2016
Views: 3591
Released On: 3/24/2016
Views: 2923
Released On: 3/17/2016
Views: 2485
Released On: 3/11/2016
Views: 2328
Released On: 3/4/2016
Views: 2622
Released On: 3/3/2016
Views: 2323
Released On: 2/23/2016
Views: 3674
Released On: 2/12/2016
Views: 2680
Released On: 2/10/2016
Views: 2390
Released On: 2/9/2016
Views: 2548
Released On: 1/20/2016
Views: 4331
Released On: 1/14/2016
Views: 4796
Released On: 1/5/2016
Views: 3025
Released On: 12/18/2015
Views: 9358
Released On: 12/9/2015
Views: 2791
Released On: 12/3/2015
Views: 3237